CYTOKINETICS IN THE NEWS
Here you can find the latest articles about Cytokinetics, along with fact sheets describing the company, our clinical programs and background on our areas of disease focus – ALS, heart failure and SMA.
|
Date |
Title |
|
| October 11, 2022 | Myosin Inhibitor Aficamten Boosts QoL, Eases Symptoms in Obstructive HCM, Medscape | |
| October 27, 2022 | Cytokinetics CEO: Why It's OK Not Being An Overnight Success | |
| August 8, 2022 | Cytokinetics Adds Decade of Trial Findings to PRO-ACT Database | |
| June 16, 2022, Evaluate | Cytokinetics aims to become the Vertex of cardiovascular disease | |
| June 2, 2022, Medscape | Myosin Activator May Benefit Data-Deprived Patients With Heart Failure and Low Blood Pressure | |
| March 31, 2022, TCTMD | Aficamten Safe, Effective for Up to 6 months in Obstructive HCM: REDWOOD-HCM OLE | |
| January 7, 2022, Fierce Biotech | Cytokinetics finds worldwide partner in Royalty Pharma for heart failure drug, snags up to $450M to extend runway | |
CYTOKINETICS FACT SHEETS
